MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$107,617,495
Issuance of common stock
from exercise of...
$845,468
Maturities of investments -
marketable securities
$41,600,000
Net cash provided by
financing activities
$108,462,963
Net cash provided by
(used in) investing...
$2,053,130
Canceled cashflow
$39,546,870
Net increase in cash
and cash...
$82,729,629
Canceled cashflow
$27,786,464
Stock-based compensation
expense
$15,309,924
Write-off of in-process
research and development
$7,357,294
Accrued expenses and
other current...
$1,401,252
Prepaid expenses and
other assets
-$532,732
Accounts payable
$146,827
Operating lease right of
use assets
$101,437
Depreciation
$60,499
Purchases of investments -
marketable securities
$39,094,847
Acquired in-process
research and development
$438,624
Purchases of equipment and
improvements
$13,399
Net cash used in
operating activities
-$27,786,464
Canceled cashflow
$24,909,965
Net loss
-$48,259,189
Prepaid research and
development
$1,920,685
Change in fair value
contingent consideration
$1,373,942
Non-cash accretion on
marketable securities
$936,975
Operating lease
liabilities
$110,517
Other assets
$95,121
Back
Back
Cash Flow
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)